These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21123810)

  • 1. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
    Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
    Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
    J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.
    Chung S; Ma X; Liu Y; Lee D; Tittiger M; Ponder KP
    Mol Genet Metab; 2007 Feb; 90(2):181-92. PubMed ID: 16979922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
    Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
    Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
    Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
    Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose enzyme replacement therapy in murine Hurler syndrome.
    Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
    Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
    Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14894-9. PubMed ID: 25267637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
    Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
    APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
    Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
    Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I.
    Brooks DA
    Expert Opin Biol Ther; 2002 Dec; 2(8):967-76. PubMed ID: 12517274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I.
    Pievani A; Azario I; Antolini L; Shimada T; Patel P; Remoli C; Rambaldi B; Valsecchi MG; Riminucci M; Biondi A; Tomatsu S; Serafini M
    Blood; 2015 Mar; 125(10):1662-71. PubMed ID: 25298037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.